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DEAR EDITOR, Pseudoxanthoma elasticum (PXE) is a multisystem
genetic disorder with cutaneous, ophthalmological and cardio-
vascular (CV) involvement.1–3 Being able to predict the natural
progression of PXE in various systems would improve preven-
tive care in those patients at elevated risk of CV or ophthalmo-
logical complications yet, the required means are still lacking.
It is unknown if each body system evolves at its own pace;
however, the skin is typically involved earlier than other sys-
tems.4 PXE skin lesions appear mainly in the first two decades
of life; initially usually at the neck and progressively extending
to other skin areas. This continues until around age 30 years.5
CV and ophthalmological complications may develop later.
We aimed to investigate potential associations between the
extent of PXE skin changes and the severity of visual and CV
manifestations.
We performed a retrospective analysis of clinical data in
patients with confirmed PXE, and monitored at our referral
centre from 2008 to 2015. PXE diagnosis was confirmed on
the basis of distinctive skin lesions, dermal elastorrhexis, oph-
thalmological signs (peau d’orange, angioid streaks, retinal
atrophy2) and/or two mutations of the ABCC6 gene. The
extent of skin involvement was estimated by enumerating the
affected skin sites, and considering the 10 typical areas usually
affected in most patients with PXE (lateral neck, anterior neck,
nape, axillary fossae, shoulder joint region, antecubital fossae,
groin, popliteal fossae, periumbilical region, mucosa of inner
aspect of the lower lip), and nine nontypical areas (oblique
mental creases, face, upper limbs excluding folds, lower limbs
excluding folds, lumbar, genital, anal, oral mucosa excluding
lower lip, other areas). ‘Affected’ areas had at least one lesion
and we encoded for skin lesion presence (1) or absence (0),
irrespective of severity. Severe ophthalmological involvement
was defined as unilateral or bilateral blindness specifically
associated with PXE (neovascular complications or primary
atrophy6). Severe CV involvement was defined as medical his-
tory of heart attack and/or stroke and/or recourse to lower
limb revascularization.
Data were expressed as median (interquartile range, IQR).
Statistical analysis was performed using SPSS 150 for Win-
dows. Mann–Whitney nonparametric testing for independent
variables was done to compare patient groups with and with-
out complications. Additionally, a multivariable logistic regres-
sion model was used to ascertain the effects of number of
affected skin lesions, age and sex on the likelihood that
patients have PXE complications. Relationships between num-
ber of affected skin areas and age were examined using Pear-
son’s correlation coefficient (r). P ≤ 005 (two-tailed)
indicated significance.
We included 125 patients (85 female; aged 10–79 years):
13% had severe CV involvement, 33% had blindness in at least
one eye, and 21% had bilateral blindness. The number of
affected skin areas was significantly higher in patients with
severe CV involvement, bilateral blindness, and blindness in at
least one eye (Table 1). A statistically significant association
was found between number of affected skin areas, age, sex
and development of complications (further detailed informa-
tion can be obtained from the corresponding author).
As expected, patients with a medical history of severe CV
involvement and/or blindness were significantly older
(Table 1). However, the number of affected skin sites corre-
lated only very slightly with age in all 125 patients (Pearson
r = 03, P = 000007). For those over 30 years [n = 95; 51
(IQR: 18) years; 9 (5) affected sites], the number of affected
Table 1 Distribution of PXE complications according to number of affected skin areas and age
n Frequency, %
Number of affected skin areas,
median (IQR) Age (years), median (IQR)
All patients 125 (85 F) 100 8 (6) 46 (28)
Complication typea With Without With Without
Severe CV involvement 16 (9 F) 13 10 (4); P = 0001 8 (6) 58 (17); P = 0006 42 (28)
At least unilateral
blindness
41 (24 F) 33 10 (3); P = 5 9 10–5 7 (7) 58 (12); P = 8 9 10–11 36 (23)
Bilateral blindness 26 (14 F) 21 11 (2); P = 9 9 10–5 8 (6) 595 (11); P = 6 9 10–8 40 (24)
F, female; IQR, interquartile range; PXE, pseudoxanthoma elasticum. aWith complications vs. without complications (Mann–Whitney test).
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skin sites did not correlate with age (Pearson r = –0006, P =
09).
Our findings indicate an association between number of
affected skin sites and severe CV events and/or ophthalmolog-
ical complications of PXE, to date, not yet demonstrated in a
large cohort. One study based on a much smaller cohort (14
Japanese patients with PXE, aged 52–85 years, four of 14
patients with PXE-associated CV events) reports similar
results.7 The authors rated six skin sites to obtain a total distri-
bution score, and demonstrated that higher distribution scores
were related to CV involvement and to the width of angioid
streaks. Furthermore, the occurrence of mucosal lesions was
associated with CV events.
One obvious limitation of our work is that our cross-sec-
tional study was conducted at a single time point. However,
there is virtually no prospect of obtaining data for longitudinal
analysis in such a rare, slowly progressive condition as PXE.
We speculate that extensive dermatological lesions might
reflect a general predisposition to mineralization, which would
further promote calcification in ocular and arterial tissue.
In conclusion, dermatologists should envisage closer moni-
toring of patients with PXE with extensive early skin signs,
including careful supervision of CV risk factors (e.g. lifestyle
adjustments such as stopping smoking and adopting regular
moderate endurance exercise) and thorough prevention of
head trauma to preclude eye involvement.
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